Literature DB >> 1631135

Isoprenoid addition to Ras protein is the critical modification for its membrane association and transforming activity.

K Kato1, A D Cox, M M Hisaka, S M Graham, J E Buss, C J Der.   

Abstract

We have introduced a variety of amino acid substitutions into carboxyl-terminal CA1A2X sequence (C = cysteine; A = aliphatic; X = any amino acid) of the oncogenic [Val12]Ki-Ras4B protein to identify the amino acids that permit Ras processing (isoprenylation, proteolysis, and carboxyl methylation), membrane association, and transformation in cultured mammalian cells. While all substitutions were tolerated at the A1 position, substitutions at A2 and X reduced transforming activity. The A2 residue was important for both isoprenylation and AAX proteolysis, whereas the X residue dictated the extent and specificity of isoprenoid modification only. Differences were observed between Ras processing in living cells and farnesylation efficiency in a cell-free system. Finally, one farnesylated mutant did not undergo either proteolysis or carboxyl methylation but still displayed efficient membrane association (approximately 50%) and transforming activity, indicating that farnesylation alone can support Ras transforming activity. Since both farnesylation and carboxyl methylation are critical for yeast a-factor biological activity, the three CAAX-signaled modifications may have different contributions to the function of different CAAX-containing proteins.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1631135      PMCID: PMC49509          DOI: 10.1073/pnas.89.14.6403

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  34 in total

1.  Solution phase synthesis of Saccharomyces cerevisiae a-mating factor and its analogs.

Authors:  C B Xue; A Ewenson; J M Becker; F Naider
Journal:  Int J Pept Protein Res       Date:  1990-10

Review 2.  Regulation of the mevalonate pathway.

Authors:  J L Goldstein; M S Brown
Journal:  Nature       Date:  1990-02-01       Impact factor: 49.962

3.  Farnesyl cysteine C-terminal methyltransferase activity is dependent upon the STE14 gene product in Saccharomyces cerevisiae.

Authors:  C A Hrycyna; S Clarke
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

4.  Posttranslational modification of Ha-ras p21 by farnesyl versus geranylgeranyl isoprenoids is determined by the COOH-terminal amino acid.

Authors:  B T Kinsella; R A Erdman; W A Maltese
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-15       Impact factor: 11.205

5.  Monoclonal antibodies to the p21 products of the transforming gene of Harvey murine sarcoma virus and of the cellular ras gene family.

Authors:  M E Furth; L J Davis; B Fleurdelys; E M Scolnick
Journal:  J Virol       Date:  1982-07       Impact factor: 5.103

6.  Specific isoprenoid modification is required for function of normal, but not oncogenic, Ras protein.

Authors:  A D Cox; M M Hisaka; J E Buss; C J Der
Journal:  Mol Cell Biol       Date:  1992-06       Impact factor: 4.272

Review 7.  Isoprenoid modification and plasma membrane association: critical factors for ras oncogenicity.

Authors:  C J Der; A D Cox
Journal:  Cancer Cells       Date:  1991-09

8.  DNA sequencing with chain-terminating inhibitors.

Authors:  F Sanger; S Nicklen; A R Coulson
Journal:  Proc Natl Acad Sci U S A       Date:  1977-12       Impact factor: 11.205

9.  Enzymatic modification of proteins with a geranylgeranyl isoprenoid.

Authors:  P J Casey; J A Thissen; J F Moomaw
Journal:  Proc Natl Acad Sci U S A       Date:  1991-10-01       Impact factor: 11.205

10.  A CAAX or a CAAL motif and a second signal are sufficient for plasma membrane targeting of ras proteins.

Authors:  J F Hancock; K Cadwallader; H Paterson; C J Marshall
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  94 in total

Review 1.  Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.

Authors:  D W End
Journal:  Invest New Drugs       Date:  1999       Impact factor: 3.850

Review 2.  Evolving therapies: farnesyltransferase inhibitors.

Authors:  W Thomas Purcell; Ross C Donehower
Journal:  Curr Oncol Rep       Date:  2002-01       Impact factor: 5.075

3.  Biochemical characterization of the Yersinia YopT protease: cleavage site and recognition elements in Rho GTPases.

Authors:  Feng Shao; Panayiotis O Vacratsis; Zhaoqin Bao; Katherine E Bowers; Carol A Fierke; Jack E Dixon
Journal:  Proc Natl Acad Sci U S A       Date:  2003-01-21       Impact factor: 11.205

4.  Exposure to oxidized low-density lipoprotein reduces activable Ras protein in vascular endothelial cells.

Authors:  Shu-Er Chow; Wing-Keung Chu; Stephen H Shih; Jan-Kan Chen
Journal:  In Vitro Cell Dev Biol Anim       Date:  2002-06       Impact factor: 2.416

5.  Agrobacterium tumefaciens-mediated transformation of the antitumor clavaric acid-producing basidiomycete Hypholoma sublateritium.

Authors:  R P Godio; R Fouces; E J Gudiña; J F Martín
Journal:  Curr Genet       Date:  2004-11       Impact factor: 3.886

6.  Endometrial cancer side-population cells show prominent migration and have a potential to differentiate into the mesenchymal cell lineage.

Authors:  Kiyoko Kato; Tomoka Takao; Ayumi Kuboyama; Yoshihiro Tanaka; Tatsuhiro Ohgami; Shinichiro Yamaguchi; Sawako Adachi; Tomoko Yoneda; Yousuke Ueoka; Keiji Kato; Shinichi Hayashi; Kazuo Asanoma; Norio Wake
Journal:  Am J Pathol       Date:  2009-12-11       Impact factor: 4.307

7.  A photoactive isoprenoid diphosphate analogue containing a stable phosphonate linkage: synthesis and biochemical studies with prenyltransferases.

Authors:  Amanda J DeGraw; Zongbao Zhao; Corey L Strickland; A Huma Taban; John Hsieh; Michael Jefferies; Wenshuang Xie; David K Shintani; Colleen M McMahan; Katrina Cornish; Mark D Distefano
Journal:  J Org Chem       Date:  2007-05-04       Impact factor: 4.354

8.  GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer.

Authors:  Anna-Karin M Sjogren; Karin M E Andersson; Meng Liu; Briony A Cutts; Christin Karlsson; Annika M Wahlstrom; Martin Dalin; Carolyn Weinbaum; Patrick J Casey; Andrej Tarkowski; Birgitta Swolin; Stephen G Young; Martin O Bergo
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 9.  Aberrant function of the Ras signal transduction pathway in human breast cancer.

Authors:  G J Clark; C J Der
Journal:  Breast Cancer Res Treat       Date:  1995-07       Impact factor: 4.872

10.  Suppression in mevalonate synthesis mediates antitumor effects of combined statin and gamma-tocotrienol treatment.

Authors:  Vikram B Wali; Sunitha V Bachawal; Paul W Sylvester
Journal:  Lipids       Date:  2009-09-24       Impact factor: 1.880

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.